The pathogen‐reduced red blood cell suspension: single centre study of clinical safety and efficacy in children with oncological and haematological diseases
- 19 February 2019
- journal article
- research article
- Published by Wiley in Vox Sanguinis
- Vol. 114 (3) , 223-231
Abstract
Background: Transmission of pathogens through blood transfusion is still of great concern to clinicians, patients and blood providers. Pathogen reduction technologies (PRT) have been successfully applied for the treatment of labile blood components, such as plasma, platelets and whole blood (WB), which are now used in routine in many countries. We report the clinical evaluation of suspension of red blood cells (RBC‐S) derived from the WB treated with riboflavin and UV light (RF+UV).Study Design and Methods: Seventy paediatric patients (0·3–17·1 years old) suffering from different malignant disorders were recruited and assigned to two groups: the control group (C) received transfusions of γ‐irradiated RBC‐S. The experimental group (T) received RBC‐S derived from WB, treated with RF+UV. Clinical efficacy was evaluated during follow‐up periods by Hb and Ht increments, and needs for transfusion support. Safety was assessed through active surveillance, recording post‐transfusion reactions, anti‐erythrocyte's antibody formation, haptoglobin and serum potassium levels.Results: The clinical efficacy of RBC‐S in both groups was similar: mean post‐transfusion Hb concentration (101·6 ± 7·57 g/l vs. 100 ± 8·3 g/l; P = 0·43), and Ht level (28·5 ± 2·42% vs. 28·2 ± 2·7%; P = 0·66). Transfusion of pathogen‐reduced RBC‐S did not increase the frequency of transfusion reactions and did not induce an excessive immune response in the follow‐up period.Conclusion: Transfusion of RBC‐S, obtained from pathogen‐reduced WB, is a promising method to increase the safety of blood component therapy for paediatric patients with malignant disorders without affecting clinical efficacy. A randomized clinical trial including more patients should follow this pilot study to confirm its results.Keywords
This publication has 38 references indexed in Scilit:
- Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st centuryTransfusion, 2012
- Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion‐associated graft‐versus‐host disease?Transfusion, 2012
- Clinical Usefulness of Haptoglobin Levels to Evaluate Hemolysis in Recently Transfused PatientsAdvances in Hematology, 2011
- Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV LightTransfusion Medicine and Hemotherapy, 2011
- The cost‐effectiveness of pathogen reduction technology as assessed using a multiple risk reduction modelTransfusion, 2010
- Mirasol Pathogen Reduction Technology®treatment does not affect acute lung injury in a two-event in vivo model caused by stored blood componentsVox Sanguinis, 2010
- Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood productsBiologicals, 2010
- Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboonsTransfusion, 2009
- Dengue and Chikungunya viruses in blood donations: risks to the blood supply?Transfusion, 2008
- Transfusion‐transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesisTransfusion, 2006